dazoxiben

Dazoxiben is an orally active small molecule that acts as a selective inhibitor of thromboxane A2 synthase (also called thromboxane synthetase), the enzyme responsible for converting prostaglandin H2 (PGH2) into thromboxane A2 (TXA2), a potent vasoconstrictor and promoter of platelet aggregation[1][3][7]. By inhibiting this enzyme, dazoxiben reduces TXA2 production, thereby decreasing platelet aggregation and vascular constriction. Dazoxiben was developed by Pfizer and investigated primarily for the treatment of Raynaud's syndrome, thrombosis, and other ischemic heart disorders[4][5][7]. While initial clinical trials showed some improvement in Raynaud's syndrome symptoms, subsequent studies did not confirm significant efficacy. The drug was also evaluated in conditions such as sepsis, adult respiratory distress syndrome, and stable angina but development was discontinued[3][7].

Other names

dazoxiben hydrochloride